Serum hyaluronic acid levels are altered in acute leukemia patients: Potential prognostic implications
Acta Haematologica Aug 19, 2017
Anagnostopoulou E, et al. – Experts sought to examine whether hyaluronic acid (HA) could serve as a possible prognostic marker in patients with acute myeloid leukemia (AML), B–acute lymphoblastic leukemia (B–ALL), and mantle–cell lymphoma (MCL). For AML, B–ALL, and MCL patients, particularly on 1 day before the initiation of chemotherapy (D0), serum HA could serve as a possible prognostic marker. Prospective case–control studies on larger populations could provide further information.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
